Search

everythinglearnresearchcommunity

for

Search:↓

The study evaluated a cream containing 4% capryloyl glycine and 1% soy isoflavonoids for its ability to inhibit ODC1 activity and manage hypertrichosis in 12 Caucasian female patients. The cream was applied to the right forearm, while a placebo was applied to the left forearm. Results showed that the cream significantly inhibited ODC1 activity by 35.1% and led to improvement in 91.7% of patients, with good efficacy in 58.3% and moderate efficacy in 41.7%. No improvement was observed with the placebo, indicating the cream's effectiveness in reducing hair growth on the forearms.

This document presents a case report of a 21-year-old female who developed dermal filler-induced alopecia, a rare complication associated with vascular occlusion and tissue ischemia following aesthetic procedures. After receiving 7 mL of hyaluronic acid filler injections in the temples, tear trough, and eyebrow glabella regions, the patient experienced localized skin necrosis and hair loss. Diagnosis was confirmed through trichoscopy, revealing follicular dropout and white dots. Treatment involved hyaluronidase injections, intralesional corticosteroids, topical minoxidil, and CO2 laser therapy, leading to complete hair regrowth and resolution of scarring over a year. The report highlights the importance of early recognition and intervention, with only 16 cases documented, emphasizing the need for awareness and adherence to safe injection practices to prevent such adverse outcomes.

This retrospective cohort study compared the efficacy and safety of baricitinib, a Janus kinase inhibitor, to traditional therapies for severe alopecia areata over a 6-month period. The study included 75 patients, with 19 receiving baricitinib. Results showed that baricitinib was more effective, with 32% and 26% of patients achieving SALT scores of ≤ 20 and ≤ 10, respectively, compared to 12% and 9% in the other treatment groups. Baricitinib also led to better secondary outcomes, with significant reductions in SALT scores. All treatments had mild-to-moderate side effects, but weight gain was noted in 16% of baricitinib-treated patients, a side effect not previously reported in clinical trials for alopecia areata. Overall, baricitinib was found to be superior to traditional treatments for severe alopecia areata.

This study focused on developing and evaluating microemulsion (ME) formulations of valproic acid (VPA) for improved transfollicular delivery in guinea pig skin. Eight stable ME formulations were created, featuring droplet sizes of 10 to 24 nm and pH levels between 4.6 and 5.2. These formulations demonstrated controlled release over 24 hours and enhanced drug delivery through both follicular and nonfollicular pathways compared to an aqueous VPA solution. The study found that formulations with higher surfactant/cosurfactant ratios improved permeation through the follicular pathway. The composition of the MEs, including oil and water content and surfactant/cosurfactant ratio, was crucial in determining the physicochemical properties and skin permeation of VPA.

This study investigated the effects of combining platelet-rich plasma (PRP) with minoxidil and finasteride/spironolactone in hair transplantation for androgenetic alopecia (AGA). Conducted from August 2019 to December 2022, it involved 30 patients divided into an experimental group, which received PRP injections alongside drug therapy and hair transplantation, and a control group, which received only drug therapy with hair transplantation. The results showed that the experimental group had significantly better follicle survival rates, follicle growth rates, and hair strength compared to the control group. The study concludes that PRP, when used with pharmacological support during follicular unit extraction (FUE) treatment for AGA, enhances hair transplantation outcomes.